Normosol-M and Dextrose (Hospira, Inc.)
Welcome to the PulseAid listing for the Normosol-M and Dextrose drug offered from Hospira, Inc.. This Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Hospira, Inc. |
| NON-PROPRIETARY NAME: | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, POTASSIUM ACETATE, and MAGNESIUM ACETATE |
| SUBSTANCE NAME: | DEXTROSE MONOHYDRATE; SODIUM CHLORIDE; POTASSIUM ACETATE; MAGNESIUM ACETATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Potassium Compounds [Chemical/Ingredient],Potassium Salt [EPC],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA],Calculi Dissolution Agent [EPC],Magnesium Ion Exchange Activity [MoA],Osmotic Laxative [EPC],Osmotic Activity [MoA],Inhibition Small Intestine Fluid/Electrolyte Absorption [PE],Increased Large Intestinal Motility [PE],Stimulation Large Intestine Fluid/Electrolyte Secretion [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 1975-08-13 |
| END MARKETING DATE: | 0000-00-00 |
Normosol-M and Dextrose HUMAN PRESCRIPTION DRUG Details:
| Item Description | Normosol-M and Dextrose from Hospira, Inc. |
| LABELER NAME: | Hospira, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 5; 234; 128; 21(g/100mL; mg/100mL; mg/100mL; mg/100mL) |
| START MARKETING DATE: | 1975-08-13 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0409-7965_b028e290-8116-4fee-a7f1-f43cd0dc1eab |
| PRODUCT NDC: | 0409-7965 |
| APPLICATION NUMBER: | NDA017610 |
Other DEXTROSE MONOHYDRATE; SODIUM CHLORIDE; POTASSIUM ACETATE; MAGNESIUM ACETATE Pharmaceutical Manufacturers / Labelers:
